Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Martinez, Osvaldo ^a   Tantral, Lee ^a   Mulherkar, Nirupama ^b   Chandran, Kartik ^b   Basler, Christopher F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN ANTIBODY; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; EBOLA VIRUS; MEMBRANE FUSION; MOUSE; MUCIN LIKE DOMAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRUS ATTACHMENT; VIRUS LIKE AGENT; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MICE; PROTEIN STRUCTURE, TERTIARY; VACCINES, VIRUS-LIKE PARTICLE; VIRAL PROTEINS;

EID: 80054735134     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir295     Document Type: Article

References (46)

1. Sanchez AG, Thomas W, Heinz F. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, ed. Fields virology. Philadelphia: Lippincott Williams and Wilkins, 2007.
2. Takada A, Robison C, Goto H, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A 1997; 94:14764-9. (Pubitemid 28041448)
3. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: Identification of receptor-deficient cell lines. J Virol 1998; 72:3155-60. (Pubitemid 28175558)
4. Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, Peters CJ. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 1998; 72:6442-7. (Pubitemid 28323957)
5. Kuhn JH, Radoshitzky SR, Guth AC, et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 2006; 281:15951-8. (Pubitemid 43848488)
6. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008; 454:177-82. (Pubitemid 351969896)
7. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001; 75:5205-14. (Pubitemid 32448543)
8. Martinez O, Johnson J, Manicassamy B, et al. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol 2010; 12:148-57.
9. Nanbo A, Imai M, Watanabe S, et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 2010; 6:e1001121.
10. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 2010; 6:e1001110.
11. Empig CJ, Goldsmith MA. Association of the caveola vesicular system with cellular entry by filoviruses. J Virol 2002; 76:5266-70. (Pubitemid 34441729)
12. Bhattacharyya S, Warfield KL, Ruthel G, Bavari S, Aman MJ, Hope TJ. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology 2010; 401:18-28.
13. Yonezawa A, Cavrois M, Greene WC. Studies of ebola virus glycoprotein- mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: Involvement of cytoskeletalproteins and enhancement by tumor necrosis factor alpha. J Virol 2005; 79:918-26. (Pubitemid 40053875)
14. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog 2008; 4:e1000141.
15. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is Necessary for infection. Science 2005; 308:1643-5. (Pubitemid 40807517)
16. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: Implications for viral entry and immunogenicity. J Virol 2010; 84:2972-82.
17. Dube D, Brecher MB, Delos SE, et al. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol 2009; 83:2883-91.
18. Kaletsky RL, Simmons G, Bates P. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol 2007; 81: 13378-84. (Pubitemid 350247834)
19. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 2006; 80:4174-8.
20. Marzi A, Akhavan A, Simmons G, et al. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J Virol 2006; 80:6305-17. (Pubitemid 43927433)
21. Alvarez CP, Lasala F, Carrillo J, Muñiz O, Corbì AL, Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002; 76:6841-4. (Pubitemid 34633551)
22. Marzi A, Möller P, Hanna SL, et al. Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DCSIGNR. J Infect Dis 2007; 196:S237-46. (Pubitemid 351417266)
23. Simmons G, Reeves JD, Grogan CC, et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003; 305:115-23. (Pubitemid 36062817)
24. Lin G, Simmons G, Pohlmann S, et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol 2003; 77:1337-46. (Pubitemid 36055556)
25. Takada A, Fujioka K, Tsuiji M, et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 2004; 78:2943-7. (Pubitemid 38314351)
26. Zampieri CA, Fortin JF, Nolan GP, Nabel GJ. The ERKmitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol 2007; 81:1230-40. (Pubitemid 46167844)
27. Martinez O, Valmas C, Basler CF. Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology 2007; 364: 342-54. (Pubitemid 46873712)
28. Okumura A, Pitha PM, Yoshimura A, Harty RN. Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol 2010; 84:27-33.
29. Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, Volchkov VE. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 2009; 83: 9596-601.
30. Alazard-Dany N, Volchkova V, Reynard O, et al. Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 2006; 87:1247-57.
31. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog 2010; 6:e1001098.
32. Francica JR, Matukonis MK, Bates P. Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology 2009; 383:237-47.
33. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010; 401:228-35.
34. Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibodymediated protection from Ebola virus. Science 2000; 287:1664-6. (Pubitemid 30127770)
35. Mupapa K, Massamba M, Kibadi K, et al. International Scientific and Technical Committee. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999; 179:S18-23.
36. Maruyama T, Rodriguez LL, Jahrling PB, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999; 73:6024-30. (Pubitemid 29274889)
37. Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3:e9.
38. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Preand postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76:6408-12.
39. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196:S400-3. (Pubitemid 351417287)
40. Warfield KL, Swenson DL, Olinger GG, Kalina WV, AmanMJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196:S430-7. (Pubitemid 351417291)
41. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 2003; 100:15889-94. (Pubitemid 38021085)
42. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol 2010; 84:163-75.
43. Sanchez AJ, Vincent MJ, Nichol ST. Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol 2002; 76:7263-75.
44. Pichlmair A, Diebold SS, Gschmeissner S, et al. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol 2007; 81:539-47. (Pubitemid 46067881)
45. Tscherne DM, Manicassamy B, Garcìa-Sastre A. An enzymatic viruslike particle assay for sensitive detection of virus entry. J Virol Methods 2010; 163:336-43.
46. Simmons G, Rennekamp AJ, Chai N, Vandenberghe LH, Riley JL, Bates P. Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. J Virol 2003; 77:13433-8.